Journal of Medical Internet Research puts AI to work on pregnancy drug-safety gaps

This is not a narrow technical problem. It is a clinical reality. Pregnant women are frequently underrepresented in clinical trials, while treatment decisions still have to be made when ideal evidence is unavailable. A physician cannot pause asthma, depression, epilepsy, infection or a chronic disease because the evidence base is incomplete. As a result, pregnancy drug safety often depends on registries, electronic health records, adverse-event reports and retrospective analysis.

In that setting, machine learning has a clear but bounded role. It can scan for patterns that humans could not practically track by hand: which medicines appear alongside which outcomes, when exposure occurred during pregnancy, where a signal repeats and where the apparent association may reflect the condition being treated rather than the drug itself. That is pharmacovigilance as an early-warning layer, not a machine issuing a clinical verdict.

The critical word is "possible." An algorithm can detect an association between exposure and outcome, but association is not causation. In pregnancy, that distinction is unusually sharp because dose, timing, maternal age, comorbidities, access to care and the underlying disease can all pull the signal in different directions. If those factors are not handled carefully, the system may look intelligent while merely describing bias in the data with more polish.

That is why the regulatory context matters. The FDA framework for pregnancy and lactation drug labeling pushes for more structured information on risk, benefit and available evidence. The CDC’s Treating for Two initiative frames the same issue from a public-health angle: pregnant patients and clinicians need better evidence about medicines already being used, not just broad warnings.

This is where machine learning can do useful work. Not by telling a clinician that a drug is simply "safe" or "unsafe," but by helping researchers separate weak signals from noise and decide what needs deeper epidemiological, clinical or regulatory review. If the models are transparent, checked for bias and treated as signal-finding tools rather than final arbiters, they can shorten the distance between scattered records and a sharper research question.

For patients, the payoff will not look like a spectacular AI revolution. It will look like a better conversation in the exam room: clearer explanation of known risks, more honest discussion of uncertainty and less reliance on thin evidence or fear. In a field where clinicians must treat disease while protecting a pregnancy, that is a meaningful gain.